# SWOSU College of Pharmacy Rural Health Network

## RURAL ROCKS

RURAL ROCKS
RECALLS
• 50% Magnesium Sulfate Injection, USP  
• Super Herbs Capsules, Weight Loss Dietary Supplement  
• Marketed as a dietary supplement  
• 5% Dextrose Injection USP  
• 8.4% Sodium Bicarbonate Injection, USP  
• Amikacin sulfate injection USP, 1 gram/4mL (250 mg/mL)  
• Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg per 100mL  
SHORTAGES 
• Numerous products
FDA Drug Safety Communication:
• FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin
HIPAA update
• Ready or Not, It’s Time For Phase 2 HIPAA Audits
INSURANCE
• New Medicare Payment Model Aims To Improve Primary Care
• Pharmacy Drug Pricing
IMMUNIZATIONS
• CDC Vaccine Price List
HOSPITAL
• Joint Commission Resources
UPDATES
• CARDIOLOGY USPSTF: Update to Aspirin Use Guidelines
• Depression May Compound Diabetes Risk  (from consultant360)
• New research investigates the association between depression and metabolic risk factors and the likelihood of developing type 2 diabetes
• New Prostate Technique May Help Men's Nighttime Urination
NEWS
• For Consumers: Seven Things Pregnant Women and Parents Need to Know About Arsenic in Rice and Rice Cereal
• Scientists Try to Stop Another Deadly Virus
• Doctors Often Overestimate Promise of Newly Approved Drugs
• Many misinterpret FDA 'breakthrough' designation, survey finds
• 3 Findings on Colds You May Have Missed
• Prediabetes May Damage Nerves More Than Thought



## RECALLS

**Dexcom Inc. Recalls G4 Platinum and G5 Mobile Continuous Glucose Monitoring System Receivers Due to Audible Alarm Failure**

o**[http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm495448.htm?source=govdelivery&utm\_medium=email&utm\_source=govdelivery](http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm495448.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery" \o "FDA)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 04/13/2016 | [Hospira](http://www.fda.gov/Safety/Recalls/ucm496111.htm) | 50% Magnesium Sulfate Injection, USP | Particulate Matter | Hospira, Inc. |
| 04/11/2016 | [Super Herbs](http://www.fda.gov/Safety/Recalls/ucm495546.htm) | Super Herbs Capsules, Weight Loss Dietary Supplement | Unapproved new drug- FDA laboratory testing found SUPER HERBS to contain sibutramine, desmethylsibutramine, and/or phenolphthalein. | Super Herbs |
| 04/05/2016 | [Continuum Labs](http://www.fda.gov/Safety/Recalls/ucm494151.htm) | Marketed as a dietary supplement | Contains Ligandrol | INVISIBLU International LLC |
| 03/28/2016 | [B. Braun Medical Inc.](http://www.fda.gov/Safety/Recalls/ucm492927.htm) | 5% Dextrose Injection USP | Leakage and visible particulate matter (microbial growth) | B. Braun Medical Inc. |
| 03/18/2016 | [Hospira](http://www.fda.gov/Safety/Recalls/ucm491476.htm) | 8.4% Sodium Bicarbonate Injection, USP | Presence of particulate matter | Hospira Inc. |
| 03/09/2016 | [Teva Pharmaceuticals](http://www.fda.gov/Safety/Recalls/ucm490003.htm) | Amikacin sulfate injection USP, 1 gram/4mL (250 mg/mL) | Due to the potential presence of particulate matter identified as glass in one vial | Teva Pharmaceuticals |
| 03/01/2016 | [Sagent Pharmaceuticals, Inc.](http://www.fda.gov/Safety/Recalls/ucm489303.htm) | Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg per 100mL |  |  |

* SHORTAGES
* April 07, 2016
* [Theophylline Extended Release Tablets and Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Theophylline%20Extended%20Release%20Tablets%20and%20Capsules&st=c&tab=tabs-4) (*Currently in Shortage*)
* April 05, 2016
* [Theophylline Extended Release Tablets and Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Theophylline%20Extended%20Release%20Tablets%20and%20Capsules&st=c&tab=tabs-4) (*Currently in Shortage*)
* March 17, 2016
* [Rivastigmine Tartrate Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Rivastigmine%20Tartrate%20Capsules&st=d&tab=tabs-4) (*Discontinuation*)
* March 11, 2016
* [Didanosine Delayed-Release Capsules USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Didanosine%20Delayed-Release%20Capsules%20USP&st=d&tab=tabs-4) (*Discontinuation*)
* [Telithromycin (Ketek) Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Telithromycin%20%28Ketek%29%20Tablets&st=d&tab=tabs-4) (*Discontinuation*)
* March 04, 2016
* [Enoxaparin Sodium Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Enoxaparin%20Sodium%20Injection&st=d&tab=tabs-4) (*Discontinuation*)
* Updated
* April 13, 2016
* [Piperacillin and Tazobactam (Zosyn) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Piperacillin%20and%20Tazobactam%20%28Zosyn%29%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* April 11, 2016
* [Calcium Gluconate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Calcium%20Gluconate%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Cefepime Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cefepime%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Cefotetan Disodium Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Cefotetan%20Disodium%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Imipenem and Cilastatin for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Imipenem%20and%20Cilastatin%20for%20Injection,%20USP&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Lidocaine Hydrochloride (Xylocaine) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20%28Xylocaine%29%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Methylprednisolone Sodium Succinate for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylprednisolone%20Sodium%20Succinate%20for%20Injection,%20USP&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Potassium Chloride Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Potassium%20Chloride%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Sodium Chloride 23.4% Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Chloride%2023.4per%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Theophylline Extended Release Tablets and Capsules](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Theophylline%20Extended%20Release%20Tablets%20and%20Capsules&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Tigecycline (Tygacil) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tigecycline%20%28Tygacil%29%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Tiopronin (Thiola)](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tiopronin%20%28Thiola%29&st=r&tab=tabs-4)   (*Resolved*)
* [Tobramycin Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tobramycin%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Vancomycin Hydrochloride for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Vancomycin%20Hydrochloride%20for%20Injection,%20USP&st=c&tab=tabs-4)   (*Currently in Shortage*)
* April 07, 2016
* [Chloroquine Phosphate Tablets](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Chloroquine%20Phosphate%20Tablets&st=r&tab=tabs-4)   (*Resolved*)
* [Potassium Acetate Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Potassium%20Acetate%20Injection,%20USP&st=c&tab=tabs-4)   (*Currently in Shortage*)
* April 05, 2016
* [Dexamethasone Sodium Phosphate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dexamethasone%20Sodium%20Phosphate%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Fentanyl Citrate (Sublimaze) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Fentanyl%20Citrate%20%28Sublimaze%29%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Meropenem for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Meropenem%20for%20Injection,%20USP&st=r&tab=tabs-4)   (*Resolved*)
* [Sufentanil Citrate (Sufenta) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sufentanil%20Citrate%20%28Sufenta%29%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* April 04, 2016
* [Atropine Sulfate Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine%20Sulfate%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Calcium Chloride Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Calcium%20Chloride%20Injection,%20USP&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Doxorubicin (Adriamycin) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Doxorubicin%20%28Adriamycin%29%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Fentanyl Citrate (Sublimaze) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Fentanyl%20Citrate%20%28Sublimaze%29%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Imipenem and Cilastatin for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Imipenem%20and%20Cilastatin%20for%20Injection,%20USP&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Lidocaine Hydrochloride (Xylocaine) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20%28Xylocaine%29%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Multi-Vitamin Infusion (Adult and Pediatric)](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Multi-Vitamin%20Infusion%20%28Adult%20and%20Pediatric%29&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Piperacillin and Tazobactam (Zosyn) Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Piperacillin%20and%20Tazobactam%20%28Zosyn%29%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Sodium Bicarbonate Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection,%20USP&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Sodium Chloride 23.4% Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Chloride%2023.4per%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Tobramycin Injection](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tobramycin%20Injection&st=c&tab=tabs-4)   (*Currently in Shortage*)
* [Vancomycin Hydrochloride for Injection, USP](http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Vancomycin%20Hydrochloride%20for%20Injection,%20USP&st=c&tab=tabs-4)   (*Currently in Shortage*)

## FDA Drug Safety Communication:

**FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin**

o   [**http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm**](http://www.fda.gov/Drugs/DrugSafety/ucm486096.htm)

managed

[**http://hmpemail.net/blaster/display.php?M=1816169&C=650bc7500c0804127d80187cd978ea9e&S=5899&L=243&N=6097**](http://hmpemail.net/blaster/display.php?M=1816169&C=650bc7500c0804127d80187cd978ea9e&S=5899&L=243&N=6097)

|  |
| --- |
| **FDA ACTIVITY** |
| [**FDA Approves Biosimilar of Johnson and Johnson's Blockbuster Drug Remicade**](http://www.firstreportnow.com/medical-resource-center/FDA) |
| The FDA has approved Inflectra (infliximab-dyyb, Celltrion Inc) for the treatment of multiple conditions, including rheumatoid arthritis and inflammatory bowel disease. |
|  |
|  |
| |  | | --- | | **FDA APPROVALS** | | [**FDA Approves Venclexta for Patients With Chronic Lymphocytic Leukemia With 17p Deletion**](http://www.firstreportnow.com/medical-resource-center/FDA) | | The FDA has approved Venclexta (venetoclax, AbbVie Inc) for the treatment of chronic lymphocytic leukemia in patients with a chromosomal abnormality called 17p deletion who have been previously treated with at least one therapy. | |
| **FDA ACTIVITY** |
| [**FDA Expands Use of Metformin to Include Patients With Renal Impairment**](http://www.firstreportnow.com/medical-resource-center/FDA) |
| Metformin-containing medications can be used in certain patients with diabetes who have mild-to-moderate kidney dysfunction. |

**HIPAA update**

**Ready or Not, It’s Time For Phase 2 HIPAA Audits**

o   [**http://www.jdsupra.com/legalnews/ready-or-not-it-s-time-for-phase-2-78715/**](http://www.jdsupra.com/legalnews/ready-or-not-it-s-time-for-phase-2-78715/)

**$1.55 million settlement underscores the importance of executing HIPAA business associate agreements**

o   <http://www.hhs.gov/about/news/2016/03/16/155-million-settlement-underscores-importance-executing-hipaa-business-associate-agreements.html>

**INSURANCE**

**New Medicare Payment Model Aims To Improve Primary Care**

o   [**http://www.consultant360.com/exclusives/new-medicare-payment-model-aims-improve-primary-care**](http://www.consultant360.com/exclusives/new-medicare-payment-model-aims-improve-primary-care)

**Pharmacy Drug Pricing**

o   [**https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Pharmacy-Pricing.html**](https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Pharmacy-Pricing.html)

**UPDATES**

**CARDIOLOGY USPSTF: Update to Aspirin Use Guidelines**

o   [**http://www.consultant360.com/exclusives/uspstf-update-aspirin-use-guidelines**](http://www.consultant360.com/exclusives/uspstf-update-aspirin-use-guidelines)

[Depression May Compound Diabetes Risk](http://www.consultant360.com/exclusives/depression-may-compound-diabetes-risk)  (from consultant360)

o   New research investigates the association between depression and metabolic risk factors and the likelihood of developing type 2 diabetes

o   [**http://www.consultant360.com/topic/mental-health**](http://www.consultant360.com/topic/mental-health)

**New Prostate Technique May Help Men's Nighttime Urination**

o   <https://www.nlm.nih.gov/medlineplus/news/fullstory_158125.html>

**IMMUNIZATIONS**

IAC Express: Weekly immunization news and information

<http://www.immunize.org/express/issue1241.asp>

**CDC Vaccine Price List**

o   <http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html>

**Zika fears escalate: Virus is scarier than previously thought, CDC says**

o   <http://www.fiercehealthcare.com/story/zika-fears-escalate-virus-scarier-previous-thought-cdc-says/2016-04-14?utm_medium=nl&utm_source=internal&mkt_tok=eyJpIjoiTjJKak5XUTNObU5rTmpsaCIsInQiOiJtcmVub0l6K05HSFVJQXFYejY5aWh4ZzVhSldNQ0psbWRnaHNkXC94T3RKdlNzaUluMXVEaUZXSkppMXBCQkxtQ1lDVVR2dm5MREkrTnBTTWNEUThnOTIxR2NtT0pKeVN6WVpuUzU3MUNpRUU9In0%3D>

**HOSPITAL**

**Joint Commission Resources**

**Patient safety**

April 13, 2016

**New Quick Safety focuses on implicit bias**

o   [**http://www.jointcommission.org/issues/article.aspx?Article=TjgKCr9s%2b3VowCidQsb%2bE4yZbhTavTj%2fu0vzpKVtAHk%3d&j=2869101&e=randygc2011@yahoo.com&l=94\_HTML&u=77598806&mid=1064717&jb=63**](http://www.jointcommission.org/issues/article.aspx?Article=TjgKCr9s%2b3VowCidQsb%2bE4yZbhTavTj%2fu0vzpKVtAHk%3d&j=2869101&e=randygc2011@yahoo.com&l=94_HTML&u=77598806&mid=1064717&jb=63)

**Upcoming events to help better understand Joint Commission requirements**

Several events are coming up in mid-May to help health care organizations with accreditation. All of the events will be held at the Westin Lombard, 70 Yorktown Shopping Center, in Lombard, Illinois:

* [Hospital Accreditation Essentials](http://www.jcrinc.com/hospital-accreditation-essentials-may-16-17-2016/): May 16-17. This interactive, solutions-based seminar is designed to provide health care professionals with implementation tips for using Joint Commission hospital requirements.
* [Maximizing Hospital Tracer Activities](http://www.jcrinc.com/maximizing-hospital-tracer-activities-may-18-2016/): May 18. This single-day event is for hospital professionals seeking an advanced workshop that includes the latest information on tracers, as well as recommendations and strategies that can be implemented at their organizations.
* [Home Care Accreditation Essentials](http://www.jcrinc.com/home-care-accreditation-essentials-may-19-20-2016/): May 19-20. This is a strategy-based seminar aimed at helping organizations with The Joint Commission’s home care requirements.

**NEWS**

**For Consumers: Seven Things Pregnant Women and Parents Need to Know About Arsenic in Rice and Rice Cereal**

o   <http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm493677.htm#1>

**Scientists Try to Stop Another Deadly Virus**

o   <https://www.nlm.nih.gov/medlineplus/news/fullstory_158128.html>

**Doctors Often Overestimate Promise of Newly Approved Drugs**

o   Many misinterpret FDA 'breakthrough' designation, survey finds

o   [**https://www.nlm.nih.gov/medlineplus/news/fullstory\_158267.html**](https://www.nlm.nih.gov/medlineplus/news/fullstory_158267.html)

**3 Findings on Colds You May Have Missed**

o   [**http://www.pharmacytimes.com/resource-centers/cough-cold/3-findings-on-colds-you-may-have-missed?utm\_source=Informz&utm\_medium=Pharmacy+Times&utm\_campaign=PT\_eNews\_Daily\_Nasacort\_4-5-16**](http://www.pharmacytimes.com/resource-centers/cough-cold/3-findings-on-colds-you-may-have-missed?utm_source=Informz&utm_medium=Pharmacy+Times&utm_campaign=PT_eNews_Daily_Nasacort_4-5-16)

**Prediabetes May Damage Nerves More Than Thought**

o   Early pain and tingling in hands, feet may be 'canary in the coal mine,' researchers say

o   [**https://www.nlm.nih.gov/medlineplus/news/fullstory\_158274.html**](https://www.nlm.nih.gov/medlineplus/news/fullstory_158274.html)

**\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\***

**This content is copyright protected**

However, if you would like to share the information in this article, you may use the headline, summary and link below:

o   [Spanish regulators suspend Inmunotek's manufacturing license and order recall](http://www.in-pharmatechnologist.com/Regulatory-Safety/Spanish-regulators-suspend-Inmunotek-s-manufacturing-license-and-order-recall?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

o   By [Gareth MacDonald+](https://plus.google.com/101368984263298352439?rel=author), 13-Apr-2016

o   Inmunotek has been ordered to recall vaccines made at a facility in Madrid after Spanish regulators identified a number of GMP deficiencies.

o   [http://www.in-pharmatechnologist.com/Regulatory-Safety/Spanish-regulators-suspend-Inmunotek-s-manufacturing-license-and-order-recall](http://www.in-pharmatechnologist.com/Regulatory-Safety/Spanish-regulators-suspend-Inmunotek-s-manufacturing-license-and-order-recall?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

**\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\***

**This content is copyright protected**

o   However, if you would like to share the information in this article, you may use the headline, summary and link below:

o   [Pill attaches to GI tract lining for slow release](http://www.in-pharmatechnologist.com/Drug-Delivery/Pill-attaches-to-GI-tract-lining-for-slow-release?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

o   By Melissa Fassbender, 11-Apr-2016

o   Researchers have developed a new tablet that attaches to the lining of the GI tract and slowly releases medication.

o   [http://www.in-pharmatechnologist.com/Drug-Delivery/Pill-attaches-to-GI-tract-lining-for-slow-release](http://www.in-pharmatechnologist.com/Drug-Delivery/Pill-attaches-to-GI-tract-lining-for-slow-release?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

**\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\***

**This content is copyright protected**

o   However, if you would like to share the information in this article, you may use the headline, summary and link below:

o   [Oasmia looking to license Vitamin A-derived drug delivery tech](http://www.in-pharmatechnologist.com/Drug-Delivery/Oasmia-looking-to-license-Vitamin-A-derived-drug-delivery-tech?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)

o   By [Dan Stanton+](https://plus.google.com/115431563038684828224?rel=author), 12-Apr-2016

o   Oasmia Pharmaceutical has announced clinical results for its XR17 nanotechnology it says validates the excipient as a potential drug delivery system.

o   [http://www.in-pharmatechnologist.com/Drug-Delivery/Oasmia-looking-to-license-Vitamin-A-derived-drug-delivery-tech](http://www.in-pharmatechnologist.com/Drug-Delivery/Oasmia-looking-to-license-Vitamin-A-derived-drug-delivery-tech?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright)